Objective To observe the preventive effect of alprostadil on contrast-induced nephropathy (CIN) in patients undergoing coronary intervention.Methods Two hundred and fifteen patients undergoing coronary intervention were divided into treatment group (112 cases) and control group (103 cases) by random digits table method.Patients in treatment group were treated routinely with addition of alprostadil (10 μ g intravenous injection every 12 h once for 7-10 days,given before surgery).Patients in control group were given routine therapy only.Complications of the two groups and CIN occurrence were observed.Results The occurrence rate of CIN in treatment group was lower than that in control group[7.1％ (8/112) vs.18.4％ (19/103),P ＜ 0.05].The occurrence rate of CIN in patients with renal insufficiency was higher than that in patients with normal renal function [51.6％ (16/31) vs.6.0％ (11/184),P ＜ 0.01].The occurrence rate of CIN in patients with diabetes was higher than that in patients without diabetes [22.1％(15/68) vs.8.2％ (12/147),P ＜ 0.01].Conclusions Alprostadil in coronary intervention before treatment can obviously reduce the incidence of CIN.CIN is more likely to occur in patients with renal insufficiency or with diabetes.

Objective To explore the clinical manifestations and the characteristics of neonatal intrahepatic cholestasis caused by Citrin deficiency(NICCD)in Hubei province. Methods The biochemical indicators including liver function,blood lipid,lactic acid,blood ammonia,total bile acid,alpha feto protein,coagulogram,blood amino spec-trum,acylcrnitine spectrum,urine organic acid and SLC25A13 gene analysis of 20 cases with NICCD,who came from Wuhan Children's Hospital,during September 2010 to January 2013,were collected before treatment,then followed up for 1 year. Results Laboratory results of NICCD patients showed high blood bilirubin,elevated liver enzymes and bile acid,hyperlipidemia,high alpha feto protein,high lactic acidosis,high ammonia,hypoalbuminemia,hypoglycemia,disor-der of blood coagulation mechanism,variety of amino acids increase,mainly citrulline rose. Mainly long - chain acyl carnitine increased among acyl of carnitine. Abnormal increase of urine 4 - hydroxy benzene acetic acid,4 - hydroxy benzene lactic acid and 4 - hydroxy benzene pyruvic acid. Six mutations were detected in SLC25A13 gene analysis,and L477R,G639S of them were novel mutations,851del4,1638ins23,IVS6 + 5G ﹥ A were hot mutation. All the patients were eased in jaundice before they were 1 year old. Conclusions The early clinical criterion of the patients is disor-der. Hyperlipidemia has been detected in the early course of the disease,and L477R,G639S are the novel mutations.

Objective To observe the protective effect of epigallocatechin gallate(EGCG)on homocysteine-induced proliferation of human aortic smooth muscle cells(HASMCs).Methods HASMCs were served as objects,which were cultured in various media,including Hcy(100,200,500,1 000 μmol/L),EGCG(EGCG 5,10,20 μmol/L),Hcy+EGCG(Hcy 500 μmol/L+EGCG 5 μmol/L,Hcy 500 μmol/L+EGCG 10 μmol/L,Hcy 500 μmol/L+EGCG 20 μmol/L)for 24 h.The proliferation of HASMCs was determined by cell counting kit-8(CCK-8)and bromodeoxyuridine(BrdU)labeling.The level of angiotensin Ⅱ(AngII)was determined by enzyme-linked immunosorbent assay(ELISA),and the level of angiotensin Ⅱ type 1 receptor(AT-1R)was determined by Western blot.Results After treatment for 24 h,compared with the control group,the proliferation of cells in different Hcy groups significantly increased(P<0.05),while the proliferation of cells in EGCG 10 and 20 μmol/L group significantly reduced(P<0.05).Compared with the Hcy 500 μmol/L group,cell proliferation significantly reduced after adding EGCG 10 and 20 μmol/L(P<0.01),while the expression levels of AngII and AT-1R decreased significantly(P<0.01).Conclusion EGCG can inhibit Hcy-induced proliferation of VSMCs.

Objective To observe the protective effect of epigallocatechin gallate(EGCG)on homocysteine-induced proliferation of human aortic smooth muscle cells(HASMCs).Methods HASMCs were served as objects,which were cultured in various media,including Hcy(100,200,500,1 000 μmol/L),EGCG(EGCG 5,10,20 μmol/L),Hcy+EGCG(Hcy 500 μmol/L+EGCG 5 μmol/L,Hcy 500 μmol/L+EGCG 10 μmol/L,Hcy 500 μmol/L+EGCG 20 μmol/L)for 24 h.The proliferation of HASMCs was determined by cell counting kit-8(CCK-8)and bromodeoxyuridine(BrdU)labeling.The level of angiotensin Ⅱ(AngII)was determined by enzyme-linked immunosorbent assay(ELISA),and the level of angiotensin Ⅱ type 1 receptor(AT-1R)was determined by Western blot.Results After treatment for 24 h,compared with the control group,the proliferation of cells in different Hcy groups significantly increased(P<0.05),while the proliferation of cells in EGCG 10 and 20 μmol/L group significantly reduced(P<0.05).Compared with the Hcy 500 μmol/L group,cell proliferation significantly reduced after adding EGCG 10 and 20 μmol/L(P<0.01),while the expression levels of AngII and AT-1R decreased significantly(P<0.01).Conclusion EGCG can inhibit Hcy-induced proliferation of VSMCs.

Monkeypox is a zoonotic disease.Previous studies have shown that children are vulnerable to monkeypox and are also at high risk for severe disease or complications.In order to improve pediatricians′ understanding of monkeypox and achieve early detection, early diagnosis, early treatment and early disposal, the committee composed of more than 40 experts in the related fields of infectious diseases, pediatrics, infection control and public health formulate this expert consensus, on the basis of the latest clinical management and infection prevention and control for monkeypox released by the World Health Organization (WHO), the guidelines for diagnosis and treatment of monkeypox (version 2022) issued by National Health Commission of the People′s Republic of China and other relevant documents.During the development of this consensus, multidisciplinary experts have repeatedly demonstrated the etiology, epidemiology, transmission, clinical manifestations, laboratory examinations, diagnosis and differential diagnosis, treatment, discharge criteria, prevention, case management process and key points of prevention and control about monkeypox.

Novel Coronavirus Pneumonia (NCP) is a class B infectious disease, which is prevented and controlled according to class A infectious diseases. Recently, children′s NCP cases have gradually increased, and children′s fever outpatient department has become the first strategic pass to stop the epidemic. Strengthening the management of the fever diagnosis process is very important for early detection of suspected children, early isolation, early treatment and prevention of cross-infection. This article proposes prevention and control strategies for fever diagnosis, optimizes processes, prevents cross-infection, health protection and disinfection of medical staff, based on the relevant diagnosis, treatment, prevention and control programs of the National Health and Health Commission and on the diagnosis and treatment experience of experts in various provinces and cities. The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children′s fever in outpatient department during the novel coronavirus pneumonia epidemic period.